Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment
Status:
Completed
Trial end date:
2017-03-28
Target enrollment:
Participant gender:
Summary
This multiple ascending dose (MAD) study in healthy subjects and subjects with mild to
moderate renal impairment will evaluate the safety, tolerability and pharmacokinetics of
KBP-5074. Safety/tolerability data and Pharmacokinetics (PK)/Pharmacodynamics (PD) (plasma
aldosterone, serum potassium, UACR and Blood Pressure) relationships will be explored to
support the selection of dosing regimens of KBP-5074 that are suitable for the Phase II/III
study.